Atsena Therapeutics’ gene therapy takes aim at childhood blindness


May 23, 2022 -- Ophthalmology-based gene therapy company Atsena Therapeutics is focused on developing novel treatments for inherited forms of blindness, with an ongoing Phase I/II clinical trial evaluating a potential therapy for patients with Leber congenital amaurosis (LCA) 1.

"Gene therapy, broadly, we're learning a lot. The field is still relatively young. Within the eye itself, we're working on the approach to solve the delivery issue and getting the vector to the right cell types," Atsena Therapeutics CEO Patrick Ritschel told ScienceBoard.net at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC.

Ritschel pointed to Atsena's laterally-spreading vector that can be administered "in one location in the eye and it will spread and cover the entire retina" to help solve the delivery issue.

LCA is the most common cause of blindness in children, impacting two to three per 100,000. LCA1 is caused by mutations in the guanylate cyclase 2D (GUCY2D) gene and results in early and severe vision impairment or blindness. LCA1-GUCY2D is one of the most common forms of LCA, affecting roughly 20% of patients who live with this inherited retinal disease.

Watch the video below to learn more.



Copyright © 2022 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.